y90 monoclonal antibody m170
mAbexperimentalADC
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 1996 (NCT00003920)
Timeline
1990s
- Jan 1, 1996
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Mucin-1INHIBITOR
MUC1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 90-Yttrium
Oral
No
Parenteral
No
Topical
No
Also known as
- y90 monoclonal antibody m170
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00009750 | Phase 1 | Mar 1, 2001 | University of California, Davis |
| NCT00009763 | Phase 1 | Mar 1, 2001 | University of California, Davis |
| NCT00003920 | Phase 1 | Apr 1, 1996 | University of California, Davis |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of California, Davis | Academic/Hospital | 3 | 3 | 1 | 1996 |
1 organizations
Page 1 / 1